Key result
Chronic aspirin and statin therapy was associated with a lower likelihood of STEMI presentation in patients with acute MI, an effect that persisted in patients with chronic kidney disease.
Why the study?
Does chronic aspirin and statin therapy reduce the probability of STEMI presentation in patients with acute MI and impaired renal function?
Cohort (n=595)
No
Does chronic aspirin and statin therapy reduce the probability of STEMI presentation in patients with acute MI and impaired renal function?
Chronic aspirin and statin therapy is associated with a lower likelihood of presenting with STEMI during an acute MI, even in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
May support chronic aspirin/statin use in CKD to lower STEMI presentation at MI; leaves open need for randomized confirmation.
Chronic use of aspirin and statins has been associated with reduced risk of subsequent myocardial infarction (MI). However, in patients with chronic kidney disease (CKD), the cardioprotective role of aspirin and statins seems to be reduced. To evaluate the impact of chronic aspirin and statin use on clinical presentation of acute MI according to renal function, the authors retrospectively analyzed 595 consecutive patients admitted to our hospital for acute MI. Renal function was normal in 404 patients and impaired in 191. Patients on therapy (113 patients) were less likely to have ST-segment elevation MI (STEMI) compared with patients not treated (36% vs 53%, respectively, P=.0002). These results have been confirmed in the population of patients with CKD (48% of STEMI in patients receiving chronic therapy and 67% in patients without therapy,P=.01). Multivariate analysis in the group of patients with CKD showed that use of aspirin or statins was an independent predictor of a decreased probability of STEMI (odds ratio, 0.5; 95% confidence interval, 0.2-1.0,P=.05). The authors' results suggest that in a community-based sample of patients with acute MI, chronic aspirin and statin therapy has a cardioprotective role that is evident also in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Sciahbasi et al. (2009) conducted a cohort in Acute myocardial infarction (n=595). Chronic aspirin and statin therapy vs. No chronic aspirin and statin therapy was evaluated on ST-segment elevation MI (STEMI) presentation (OR 0.5, 95% CI 0.2-1.0, p=.0002). Chronic aspirin and statin therapy was associated with a lower likelihood of STEMI presentation in patients with acute MI, an effect that persisted in patients with chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: